ENLV
Enlivex Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.21
+1.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 214.0K | 332.0K | 545.0K | 835.0K | 777.0K |
| Gross Profit | (214.0K) | (332.0K) | (545.0K) | (835.0K) | (777.0K) |
| Operating Expenses | |||||
| R&D Expense | 10.7M | 8.9M | 10.1M | 19.2M | 18.7M |
| SG&A Expense | 9.7M | 5.7M | 4.9M | 6.1M | 6.7M |
| General & Admin Expense | 9.7M | 5.7M | 4.9M | 6.1M | 6.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (103.0K) | 61.0K | (48.0K) | 4.0M | 402.0K |
| Total Operating Expenses | 20.4M | 14.7M | 15.0M | 29.4M | 25.8M |
| Cost and Expenses | 20.6M | 15.0M | 15.5M | 29.4M | 25.8M |
| Operating Income (EBIT) | (20.6M) | (15.0M) | (15.5M) | (29.4M) | (25.8M) |
| Non-Operating | |||||
| Interest Income | 660.0K | 792.0K | 1.1M | 1.6M | 835.0K |
| Interest Expense | 1.3M | 13.0K | 13.0K | 14.0K | 5.3M |
| Net Interest Income | (1.3M) | 779.0K | 1.1M | 1.6M | (4.4M) |
| Other Non-Op Income/Expense | 5.4B | 1.6B | 522.0K | 327.0K | (5.3M) |
| Non-Operating Income (excl Interest) | (352.0K) | — | (522.0K) | (341.0K) | — |
| EBT (Pre-Tax Income) | 5.3B | 1.6B | (15.0M) | (29.1M) | (31.1M) |
| Income Tax Expense | 1.2B | 382.6M | — | — | — |
| Bottom Line | |||||
| Net Income | 4.1B | 1.2B | (15.0M) | (29.1M) | (31.1M) |
| Earnings from Cont. Ops | 4.1B | 1.2B | (15.0M) | (29.1M) | (31.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 4.1B | 1.2B | (15.0M) | (29.1M) | (31.1M) |
| Per Share | |||||
| Basic EPS | $577.48 | $405.60 | ($10.95) | ($23.40) | ($34.65) |
| Diluted EPS | $537.52 | $382.20 | ($10.95) | ($23.40) | ($34.65) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 16.5M | 3.0M | 1.4M | 1.2M | 1.2M |
| Diluted Shares Outstanding | 19.3M | 3.2M | 1.4M | 1.2M | 1.2M |
| Profitability Metrics | |||||
| EBITDA | (19.9M) | (14.7M) | (14.5M) | (28.2M) | (25.0M) |
| D&A | 278.0K | 332.0K | 545.0K | 835.0K | 777.0K |
| EBIT | (20.2M) | (15.0M) | (15.0M) | (29.1M) | (25.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026